Ribociclib (LEE011) Rollover Study for Continued Access
Ribociclib (LEE011) Rollover Study for Continued Access
Active, not recruiting · NCT02934568 · Registry updated 2026-04-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ribociclib (LEE011) Rollover Study for Continued Access | Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | Active, not recruiting | Phase 2 | 2026-04-16 | NCT02934568 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Broome Oncology | Johnson City | United States | 4 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| St Jude Childrens Research Hospital | Memphis | United States | 6 |
| The Regents of the Uni of Michigan | Ann Arbor | United States | 1 |
| University of Alabama at Birmingham | Birmingham | United States | 8 |